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INCREASED COSTS AFTER ALLOGENEIC HAEMATOPOIETIC SCT ARE AS-
SOCIATED WITH MAJOR COMPLICATIONS AND RE-TRANSPLANTATION
Svahn, B.-M.1, Remberger, M.1, Alvin, O.2, Karlsson, H.1, Ringden, O.1
1Karolinska Institutet Karolinska University Hospital Huddinge, Stock-
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We wanted to evaluate factors associated with high costs after al-
logeneic hematopoietic stem cell transplantation (HSCT). We col-
lected all in-patient and out-patient costs during the first year after
HSCT over five years, from 2003 to 2007. Mean one-year costs per
patient were V141,493 (95% CI 5 125,019 to 157,967). Patients
treated with non-myeloablative conditioning had reduced costs,
but patients treated with reduced-intensity or myeloablative condi-
tioning had similar one-year costs. Multivariate analysis showed
that increased one-year costs were seen in post-transplant complica-
tions: rejection (RH 1.24, p\0.001), acute graft-versus-host disease
(GVHD) of grades III–IV (1.31, p\0.001) and invasive fungal infec-
tion (1.15, p 5 0.02). In addition, increased costs were associated
with re-transplantation (1.21, p 5 0.001), mesenchymal stem-cell
therapy (1.26, p\0.001) unrelated donor transplants (1.20, p 5
0.002), and the need for granulocyte colony-stimulating factor
treatment due to poor engraftment (1.12, p 5 0.047). In patients
without any of these risk factors, mean one-year costs were
V84,773 (95% CI 71,145-98,400) (n 5 51). With three risk factors,
the cost increased toV249,775 (166,824-332,727) (n5 14). To con-
clude, major complications increased the costs of HSCT. Unrelated
donor transplants were more expensive than HLA-identical sibling
transplants. Costs were reduced in patients treated with non-mye-
loablative conditioning.
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RISK FACTORS FOR RELAPSE IN PATIENTS WITH MYELOID
MALIGNANCIES
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Background:The past ten years, there has been an increase in using
reduced intensity conditioning regimens (RIC) in allogeneic stem
cell transplantation (SCT) for different diseases. Long term effects
of these conditioning regimens on outcome factors like relapse is
now being investigated in different studies. In this study, we studied
risk factors for relapse in patients with acute myeloid leukemia
(AML) and myelodysplastic syndrome (MDS).
Patients: 267 patients transplanted between 1999 and 2011 were in-
cluded.Most patients had AML (n5 193) and 74 hadMDS. RICwas
given to 92 patients and myeloablative conditioning (MAC) to 175
patients. The RIC regimens consisted mainly of a combination of
Fludarabine and Busulphan.
Results: Four different risk factors for relapse were found in univar-
iate analysis.
(1) Unrelated transplantation (33% relapse incidence at 5 years) vs
sibling transplants (22%), p 5 0.05.
(2) AcuteGVHD, anygrade, (23%) vs no aGVHD(40%), p5 0.02.
(3) RIC (37%) vs MAC (26%), p 5 0.02.
(4) A donor sero-positive for 3-4 herpes viruses (CMV,HSV,VZV
and EBV) was correlated with decreased incidence of relapse (27%),
compared to if the donor was positive for only 0-2 of these viruses
(38%), p 5 0.03.
Higher relapse risk in unrelated donor SCT is partly explained by
the use of ATG in these patients. Especially in unrelated transplants
with RIC, ATG in combination with long immunosuppression may
have hampered the antileukemia effect. In fact, the highest risk of re-
lapse was found in unrelated transplants with RIC (40%).
In sibling transplants, no effect of RIC on relapse was found.
In multivariate analysis, the most significant factor for relapse was
donor virus serology.
Conclusion: In this study, we could find that the use of ATG in un-
related transplants after RIC was correlated with high risk of relapse.
Interestingly, the donor virus serology seems to have an effect on re-
lapse. It may be speculated that donor T-cells with previous virus in-
fections may be more immune reactive. It could also be that virus
specific T-cells may cross-react with leukemia cells.365
REDUCED INTENSITY CONDITIONING WITH PENTOSTATIN AND LOW-
DOSE TBI IN PATIENTS WITH RELAPSED HEMATOLOGIC MALIGNANCIES
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Reduced intensity conditioning regimens have been developed
which have resulted in successful engraftment of allogeneic stem
cells with reduced regimen-related toxicities.We previously demon-
strated in a Phase II study that a regimen of extracorporeal photo-
pheresis (ECP), pentostatin (4mg/m2 CIVI days -5 and -4) and
600 cGy of TBI was associated with stable engraftment, a NRM of
11% and a reduced incidence of acute and chronic GVHD. We
now report results from 37 pts with lymphoid malignancies treated
with pentostatin and TBI 600cGy (days -3 and -2) followed by allo-
geneic stem cell infusion. Three pts with T-cell lymphomas who re-
ceived ECP as part of the regimen on days -7 and -6 are included.
Median age was 59yrs (range 20-69). Indications for transplant
were B-NHL (17 pts), B-ALL (6 pts), PTCL (9 pts), CTCL (3
pts) and T-ALL (2 pts). Four pts had prior autologous transplant
and 1 had prior alloBMT for ALL. Based on CIBMTR disease clas-
sification, 68% (15pts) were intermediate or high risk. Donors were
matched related (MRD) in 18 pts, matched unrelated (MUD) in 12,
and mismatched unrelated (MMUD) in 7. Tacrolimus/Mycopheno-
late (Tac/MMF) were used for GVHD prophylaxis in 30 pts with
MRD or MUD, and Tacrolimus/Sirolimus/Methotrexate (Tac/
Rapa) were used in the 7 pts withMMUD. Filgrastrim was routinely
used from day +7 to engraftment in all but 1pt. There were no graft
rejections. The 100-day TRMwas 8%. At a median follow up of 428
days, the median survival has not been reached; 24 (65%) pts are alive
and 92% are in remission. The median overall PFS was 18.2 mo, and
PFS for the int/high risk pts was 16.4 mo. There was no difference in
OS or PFS betweenCIBMTR low and int/high risk groups (p5 0.90
and 0.77 respectively). Of the 8 pts with ALL, 3 relapsed and 5 died
(2 with GVHD). Incidence of acute GVHD grade 3-4 was 11%
(38% for grade 2-4). Extensive chronic GVHD occurred in 11 pts
(30%). Infectious complications included bacteremia in 18 pts,
CMV reactivation in 16 pts, and HHV-6 in 4 pts. There were no
invasive fungal infections. Regimen related toxicities included renal
insufficiency in 4 pts who received Tac/Rapa and 1 pt who received
Tac/MMF. One pt died from TTP (thrombotic microangiopathy)
and DAH (diffuse alveolar hemorrhage). In summary, these results
demonstrate that this regimen of infusional pentostatin and low-dose
TBIwas well tolerated and associated with significant disease control
in both low and high risk patients with lymphoid malignancies.
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MYELOID LEUKEMIA: NO INCREASE IN RELAPSE WITH ALEMTUZU-
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The role of T cell depletion in allogeneic stem cell transplantation
for acute myeloid leukemia (AML) remains uncertain. T cell deple-
tion has the capacity to reduceGVHD-related toxicity, an important
issue for the majority of patients requiring a transplant who do not
have an HLA-matched related donor available, but there are con-
cerns about a potential reciprocal increase in relapse risk. This study
describes the results in 56 consecutive adults with high-risk AML
transplanted with an alemtuzumab-containing myeloablative regi-
men, which provides partial T cell depletion, using HLA-matched
or mismatched unrelated donors.
AML developed de novo in 50 patients (89%) and was secondary
in 6 (3 transformedMDS; 3 therapy-related AML). All patients were
high-risk for relapse, as defined by induction failure, adverse cytoge-
netics (-5, -7, del(5q), abnormal 3q or complex5.4 abnormalities),
.CR1, or secondary disease. 13/56 (23%) had refractory disease at
transplant. The median age at transplant was 36 years (16-57) and
22 (39%) donors were HLA-mismatched at#3/10 loci (12 x1 locus,
9 x2, 1 x3). Patients received fludarabine 30mg/m2/day D–9 to -7,
